Liver transplantation
Liver transplantation has been studied in 82 papers since 1997: 1 trial and 52 observational studies in people, 5 in animals, 22 reviews; 27 in the past year. Its furthest trials in people are at phase 3. The newest paper, Nov 7, 2026: “Evolution and impact of sarcopenia and myosteatosis in the context of liver transplantation”.
Research on it is growing 9% slower than aging research as a whole: 13 papers in the latest year counted
2 new papers in 30 daysSee all 81 papers on liver transplantation
At a glance
Liver transplantation is linked with lower mortality in people with cirrhosis, and independent labs report lower frailty in human recipients. One study reports higher frailty at three months but lower frailty at 12 months; cohorts also link transplantation with higher coronary disease risk. Some papers declare company ties, and an author has a company affiliation.
38 findings in 29 papers from 1997 to 2026, 7 of them since April 2026
Independent labs found the same change in people. 20 independent labs in 13 countries; 9 trials, none about aging, 1 with no results posted.
“The median pretransplant LFI was 3.9, showing minimal change at 3 mo (3.8; P = 0.331) and improvement at 6-mo post-LT (3.6; P = 0.001).”
1 of its findings points the other way.
- 20 independent labs in 13 countries
- 1 finding against
- 9 trials, none about aging, 1 with no results posted
- Funders: National Institutes of Health and others
- 6 of 32 findings with company ties
- Human trial1
- Humans52
- Animals5
- In silico1
What did studies of liver transplantation find?
19Studies of liver transplantation measured 19 outcomes, among them frailty, lifespan and survival.
Frailty
downin humans2upin humans1
2 studies
Frailty
downin humans2upin humans1
Liver transplantation decreases frailty in humans (post-liver transplantation) (median 3.9 to 3.6, P = 0.001).
Human trialpost-liver transplantation6 mo
Liver transplantation is linked with lower frailty in humans (median LFI 3.4 at 12 months vs 3.7 pretransplant).
Humans12 months posttransplantn = 107
Liver transplantation is linked with higher frailty in humans (median LFI 3.7 pretransplant to 3.9 at 3 months).
Humans3 months posttransplantn = 178
Lifespan
upin humans1upin rats1
2 studies
Lifespan
upin humans1upin rats1
Liver transplantation increases lifespan in humans (post-liver transplantation).
Reviewpost-liver transplantation
Liver transplantation extends lifespan in rats (arterialized, orthotopic liver transplantation) (48.1 to 52.4 months).
Animalsarterialized, orthotopic liver transplantationlivermales
Survival
upin humans1
1 study
Survival
upin humans1
Liver transplantation improves survival in humans across full spectrum of frailty severity.
Reviewacross full spectrum of frailty severity
Pyroptosis
upin mice1
1 study
Pyroptosis
upin mice1
Liver transplantation increases pyroptosis in mice (aging donor graft versus young graft).
Animalsaging donor graft versus young graftaging donor graftKupffer cells
Ischemia-reperfusion injury
upin mice1
1 study
Ischemia-reperfusion injury
upin mice1
Liver transplantation increases ischemia-reperfusion injury in mice (aging donor graft versus young graft).
Animalsaging donor graft versus young graftaging donor graftliver
Biological-age acceleration
no changein humans1
1 study
Biological-age acceleration
no changein humans1
Liver transplantation was not clearly linked with biological-age acceleration in humans.
Humanspbmc
Apoptosis
upin rats1
1 study
Apoptosis
upin rats1
Liver transplantation increases apoptosis in rats (aged donor grafts).
Animalsaged donor graftsperibiliary gland
LAMC1
downin rats1
1 study
LAMC1
downin rats1
Liver transplantation decreases LAMC1 in rats (aged donor grafts).
Animalsaged donor graftsperibiliary gland
Cell detachment
upin rats1
1 study
Cell detachment
upin rats1
Liver transplantation induces cell detachment in rats (aged donor grafts).
Animalsaged donor graftsperibiliary gland168 h
Coronary artery calcification
upin humans1
1 study
Coronary artery calcification
upin humans1
Liver transplantation is linked with higher coronary artery calcification in liver transplant recipients vs matched controls (26.2% vs. 9.2%, p < 0.0001).
Humansin liver transplant recipients vs matched controls
All 19Fewer
What is liver transplantation linked with?
15Studies link liver transplantation with 15 measures, among them sarcopenia, cancer and chronic kidney disease.
Sarcopenia
downin humans1mixedin humans1
2 studies
Sarcopenia
downin humans1mixedin humans1
Liver transplantation is associated with sarcopenia in humans (Cirrhotic patients undergoing liver transplantation) (p=0.034).
HumansCirrhotic patients undergoing liver transplantationskeletal muscle12 months
Sarcopenia is associated with liver transplantation in recipient.
Reviewin recipientliver
Cancer
upin humans1+23%
1 study
Cancer
upin humans1+23%
Liver transplantation is linked with a higher risk of cancer in humans (23%).
Humans≥30 yn = 138
Chronic kidney disease
upin humans1+70%
1 study
Chronic kidney disease
upin humans1+70%
Liver transplantation is linked with a higher risk of chronic kidney disease in humans (70%).
Humans≥30 yn = 138
Immune response
upin humans1
1 study
Immune response
upin humans1
Liver transplantation is associated with immune response in humans (211 DMRs).
Humanspbmcbetween five and ten years post-transplant
miRNA expression
mixedin humans1
1 study
miRNA expression
mixedin humans1
Liver transplantation is associated with miRNA expression in humans (regenerating vs nonregenerating phases post-liver transplantation).
Humansregenerating vs nonregenerating phases post-liver transplantationplasman = 12
SCORE2
no changein humans1
1 study
SCORE2
no changein humans1
Liver transplantation is associated with SCORE2 in humans (P = 0.20).
Humans
High-risk plaque
upin humans1OR 2.1
1 study
High-risk plaque
upin humans1OR 2.1
Liver transplantation is associated with high-risk plaque in humans among individuals with any coronary atherosclerosis (OR: 2.10; 95% CI: 1.29-3.45).
Humansamong individuals with any coronary atherosclerosis
Coronary atherosclerosis
upin humans1OR 2.19
1 study
Coronary atherosclerosis
upin humans1OR 2.19
Liver transplantation is associated with coronary atherosclerosis in humans (adjusted for age, sex, hypertension, diabetes, dyslipidemia, smoking, and obesity) (OR: 2.19; 95% CI: 1.48-3.27).
Humansadjusted for age, sex, hypertension, diabetes, dyslipidemia, smoking, and obesity
Coronary artery disease
upin humans1
1 study
Coronary artery disease
upin humans1
Liver transplantation is associated with coronary artery disease in humans (Liver transplant recipients compared with population controls) (aHR 2.02, 95% CI 1.80–2.30).
HumansLiver transplant recipients compared with population controlsMedian follow-up of 8.0 years63% mensn = 2,925
Serum and urinary metabolite concentrations
upin humans1
1 study
Serum and urinary metabolite concentrations
upin humans1
Liver transplantation is associated with serum and urinary metabolite concentrations in humans After liver transplantation.
HumansAfter liver transplantationSerum and urine
All 15Fewer
Has liver transplantation been tested in people?
0 of 9 about agingYes: 1 trial and 52 observational studies in people have been published, and 9 trials are registered.
In trials
Phase 2Terminated1 trial
Phase 2Terminated1 trial
Phase 2Status unknown1 trial
Gallbladder neoplasm
Phase 2Terminated1 trial
Phase 2Terminated1 trial
Phase 2Recruiting1 trial
All 10Fewer
Stopped
NCT01151761TerminatedBile duct neoplasm
Poor accrual
Trial sponsors
1 trialPhase 3236 people
2 trialsPhase 245 people
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
1 trialPhase 259 people
The First Affiliated Hospital with Nanjing Medical University
1 trialPhase 225 people
ANRS, Emerging Infectious Diseases
1 trialPhase 215 people
1 trialPhase 22 people
National Institute of Allergy and Infectious Diseases
1 trialPhase 115 people
1 trial10 people
Funding
12 grants since 2017National Institute on Aging$10.4MNational Institute of Diabetes and Digestive and Kidney Diseases$2.9MJapan Society for the Promotion of Science¥10.8M
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of California, San Francisco$702K2023–2028
National Institute on AgingUniversity of California, San Francisco$1.5M2018–2028
National Health and Medical Research CouncilUniversity of SydneyA$2M2026–2028
Prognostic biomarkers of allograft in pediatric liver transplantation
Japan Society for the Promotion of ScienceJichi Medical University¥2.3M2024–2027
Agencia Nacional de Investigación y DesarrolloPontificia Universidad Catolica de ChileCLP 234K2024–2028
Immunometabolic impact of machine perfusion strategies in liver transplantation
UKRI | Medical Research CouncilKing's College London£1.2M2023–2026
Gouvernement du Canada | Canadian Institutes of Health ResearchUniversity of AlbertaCA$956K2022–2026
Home-based EXercise and motivAtional programme before and after Liver Transplantation: ExaLT trial
National Institute for Health ResearchUniversity of Birmingham£1.5M2021–2026
National Institute on AgingUniversity of California, San Francisco$202K2020–2022
Japan Society for the Promotion of ScienceTohoku University¥3.9M2021–2025
Contains public sector information licensed under the Open Government Licence v3.0.
How this record changed
Summary written from the findings.